KaliVir Immunotherapeutics Raises $14M Series A Extension

KaliVir Immunotherapeutics has successfully closed a $14 million Series A financing extension, bolstering its total Series A capital to $25 million. This significant influx of funding is earmarked to accelerate the clinical development of its lead oncolytic immunotherapy candidate, VET3-TGI, which targets advanced solid tumors. The investment underscores growing confidence in the company's innovative approach to cancer treatment.

The latest funding round was spearheaded by Company K Partners, with crucial participation from SV Investment and Flexus Partners. Reinforcing their commitment, existing backers, including affiliates of Nextrans and Quad Investment Management, also contributed to the extension. This financial reinforcement positions KaliVir to make substantial progress in its ongoing clinical trials and corporate objectives.

Proceeds from this financing will primarily fuel the advancement of VET3-TGI through the ongoing STEALTH-001 Phase 1/1b clinical trial. This includes continued patient recruitment and the progression of the trial's dose-escalation and expansion phases. The funds will also support general corporate operations, ensuring a stable foundation for the company's strategic initiatives.

The oncolytic immunotherapy candidate, VET3-TGI, is built upon KaliVir's proprietary Vaccinia Enhanced Template (VET) platform. This advanced technology is engineered to selectively replicate within tumor cells, thereby triggering a localized immune response and modifying the immunosuppressive tumor microenvironment. By expressing IL-12 and a TGFβ inhibitor, VET3-TGI is designed with multiple mechanisms to amplify anti-tumor immunity, a critical factor in overcoming treatment resistance in advanced cancers.

The STEALTH-001 study is a first-in-human, open-label trial evaluating VET3-TGI in patients with advanced, unresectable, or metastatic solid tumors. The therapy is being assessed via both intratumoral injection and intravenous infusion, both as a monotherapy and in combination with atezolizumab. The company reports that the trial is progressing as planned through its dose-escalation phase, indicating positive momentum in the validation of their therapeutic approach.

In conjunction with the financing, KaliVir has expanded its board of directors with the addition of seasoned industry experts. Woo Young Kim from Company K Partners, Kwang Ha Jung of SV Investment, and JP Hong from Flexus Partners have joined the board. Their collective expertise in life sciences is expected to provide invaluable strategic guidance as KaliVir navigates its next phase of growth and clinical development.

The biotechnology sector, particularly the field of immuno-oncology, continues to attract significant investment as companies strive to develop more effective and targeted cancer therapies. The oncolytic virus market, projected to grow substantially in the coming years, is seeing innovation focused on enhancing payload delivery and immune stimulation. KaliVir's platform, with its focus on systemic delivery and selective transgene expression within tumors, addresses key challenges in the field, positioning VET3-TGI as a potentially differentiated therapeutic option for patients with limited treatment alternatives.